AzTrials
AzTrials

Disruptive Mood Dysregulation DisorderNCT01862549

Adapting DBT for Children With DMDD: Pilot RCT

A study testing Dialectical Behavior Therapy for children and Treatment as Usual in people with Disruptive Mood Dysregulation Disorder, run by Weill Medical College of Cornell University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study examines feasibility and preliminary efficacy of Dialectical Behavior Therapy adapted to children (DBT-C). DBT-C as compared to treatment-as-usual (TAU) is hypothesized to have lower drop-out rate, and higher treatment attendance and satisfaction. Read more about this study

Who is it for?
Ages 7 to 12 years
Conditions the study is for
Disruptive Mood Dysregulation Disorder
What is being tested?
Dialectical Behavior Therapy for children and Treatment as Usual
Could I receive a placebo?
No, everyone receives an active treatment
How many people
43 participants
Where
1 siteUnited States
Study dates
May 2013to Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Ages 7 years 0 months to 12 years 11 months
  • Meet criteria for Disruptive Mood Dysregulation Disorder on DSM-IV
  • Stabilized on psychiatric medication (at least 6 weeks).
  • Able to be treated on the outpatient basis
  • Children with suicidal ideation, suicidal behavior and non-suicidal self-injury will be included (assessed using Columbia Suicide and Self-Injury Severity Rating Scale) unless other interventions are indicated (e.g., hospitalization, medication).

Who cannot join

  • Documented cognitive disability ( if records are not available will use < 85 IQ on Wechsler Intelligence Scale for Children-IV Information and Block Design subtests).
  • Current diagnosis of a psychotic disorder (on K-SADS-PL)
  • Pervasive Developmental Disorder (on K-SADS-PL)
  • Child in the English as Second Language program at school and/or caregivers have language difficulties as per self-report
  • Child is in state custody.
  • As consistent with DMDD diagnosis, child's co-morbid conditions better account for disruptive mood.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Weill Cornell Medical College

    White Plains, New York, 10605

Other trials in United States

About this study

Official title: Adapting Dialectical Behavior Therapy for Children With Disruptive Mood Dysregulation Disorder: Pilot Randomized Clinical Trial

This study examines feasibility and preliminary efficacy of Dialectical Behavior Therapy adapted to children (DBT-C). DBT-C as compared to treatment-as-usual (TAU) is hypothesized to have lower drop-out rate, and higher treatment attendance and satisfaction. Further, DBT-C as compared to TAU will have significantly greater reduction in symptoms of Disruptive Mood Dysregulation disorder, including verbal and behavioral outbursts and angry/irritable mood.

Read the detailed description

Specific Aims:

I: Conduct Pilot Randomized Clinical Trial to evaluate feasibility and efficacy of DBT for children with Disruptive Mood Dysregulation Disorder (DMDD) as compared with Treatment-As-Usual (TAU) (up to 30 children and caregivers in DBT-C and up to 30 children and caregivers in the treatment as usual comparison condition).

Specific Aim 1: Examine feasibility of DBT-C by evaluating the drop-out rates, number of session attended, and treatment satisfaction and any differences in these rates by groups, as well as therapist treatment adherence and competence.

Hypothesis 1: Attendance rate in DBT-C, as compared to TAU, will be at least 10% higher and drop-out rate will be at least 10% lower (primary feasibility endpoint). Further, DBT-C, as compared with TAU will have significantly higher treatment satisfaction rating by subjects (on the child and caregiver Therapy Satisfaction Questionnaires), and by therapists (on Therapist Satisfaction Scale), and higher patient compliance (on Psychosocial Treatment Compliance Scale). Therapist treatment adherence and competence as measured by DBT-C Treatment Integrity Scale, will not fall below 80%.

Specific Aim 2: Examine preliminary efficacy of DBT-C in reducing symptoms of Disruptive Mood Dysregulation Disorder.

Hypothesis 2: Children in DBT-C condition as compared to TAU will have significantly greater reduction in irritability, anger, aggression, temper outbursts, and mood instability (on Clinical Global Impression - Improvement scale [primary categorical outcome] Exploratory Aim 3: Examine efficacy of DBT-C in improving adaptive coping skills, emotional and behavioral regulation, social skills, and reducing aggressive behaviors, affective reactivity, non-suicidal self-harm behaviors, suicidal ideations, suicidal attempts, and non-suicidal self-harm urges.

Hypothesis 3: Children in DBT-C condition as compared to TAU will have significantly greater improvement in adaptive coping skills (on the Children's Coping Strategies Checklist), emotional and behavioral regulation (on the Emotion Regulation Checklist and Child Behavior Checklist - Dysregulation Syndrome) and social skills (on the Social Skills Rating Scale), and significantly greater reduction in aggressive behaviors (Measure of Aggression, Violence and Rage in Children), affective reactivity (on the Affective Reactivity Index and Mood Symptoms Questionnaire). ), and greater reduction in non-suicidal self-harm behaviors (in Columbia Suicide and Self-Injury Severity Rating Scale [C-SSIS] self-injurious behaviors), suicidal ideations (in the C-SSRS suicidal ideation classification category), suicidal attempts (in C-SSIS suicide attempts category), and non-suicidal self-harm urges (in C-SSIS self-injurious urges, no suicidal intent category).

Exploratory Aim 4: Examine efficacy of DBT-C in reducing the need for higher level services.

Hypothesis 4: Children in DBT-C condition as compared to TAU will have significantly fewer psychiatric hospitalization, emergency room visits, total number of days inpatient, and residential care placements (on the Services Assessment Form).

Exploratory Aim 5: Examine whether parent emotion regulation moderate the relationship between intervention and outcomes, while parent ability to effectively cope with children's negative emotions and children's coping skills and emotion regulation mediate outcomes.

Hypothesis 5: Parents' own emotion regulation (on the Difficulties in Emotion Regulation Scale) will moderate outcomes and parents' ability to effectively cope with children's negative emotions (on the Parental Response to Children's Negative Emotions), children coping skills (on the Children's Coping Strategies Checklist) and emotion regulation (on Emotion Regulation Checklist) will mediate outcomes.

Being tested
Dialectical Behavior Therapy for children, Treatment as Usual

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01862549
Study groupRoleWhat they receive
DBT for childrenExperimentalDialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
Receives: Behavioral: Dialectical Behavior Therapy for children
Treatment as UsualActive comparatorChildren in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
Receives: Behavioral: Treatment as Usual

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Attendance and drop-out rate measure

    Measured: 32 weeks

  2. Therapy Satisfaction Questionnaire

    Measured: 32 weeks

  3. Therapist Satisfaction Questionaire

    Measured: 32 weeks

  4. Psychosocial Treatment Compliance Scale

    Measured: 32 weeks

Secondary outcomes (12)
  1. Clinical Global Impression Scale

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  2. Mood Symptoms Questionnnaire

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  3. Children Coping Strategies Checklist

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  4. Emotion Regulation Checklist

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  5. Child Behavior Checklist

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  6. Social Skills Rating Scale

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  7. Measure of Aggression, Violence and Rage in Children

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  8. Affective Reactivity Index

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  9. Columbia Suicide and Self-Injury Serevity Rating Scale

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  10. Services Assessment Form

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  11. Difficulties in Emotion Regulation Scale

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

  12. Parental Response to Children's Negative Emotions Scale

    Measured: pre-treatment, 8, 16, 24, 32 weeks, 3-month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 May 2013 (estimated)
  2. Study startMay 2013
  3. Primary completionDec 2015
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
43 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01862549
Sponsor's protocol ID
1205012350
Status last verified
Feb 2019
First submitted
20 May 2013
Last updated
1 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Perepletchikova F, Nathanson D, Axelrod SR, Merrill C, Walker A, Grossman M, Rebeta J, Scahill L, Kaufman J, Flye B, Mauer E, Walkup J. Randomized Clinical Trial of Dialectical Behavior Therapy for Preadolescent Children With Disruptive Mood Dysregulation Disorder: Feasibility and Outcomes. J Am Acad Child Adolesc Psychiatry. 2017 Oct;56(10):832-840. doi: 10.1016/j.jaac.2017.07.789. Epub 2017 Aug 10.

    PubMed 28942805

Questions about this trial

What is this clinical trial studying?

A study testing Dialectical Behavior Therapy for children and Treatment as Usual in people with Disruptive Mood Dysregulation Disorder, run by Weill Medical College of Cornell University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Attendance and drop-out rate measure (time frame: 32 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01862549, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in